Investigating how BATF regulates natural killer cell growth and function
BATF as an inducible regulator of natural killer cell expansion and effector function
This study is looking at how a protein called BATF affects natural killer (NK) cells, which help our bodies fight off viruses and cancer, to see if changing BATF levels can make these cells work better and improve treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11073649 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of BATF, a transcription factor, in the development and function of natural killer (NK) cells, which are crucial for fighting viral infections and tumors. The study will explore how manipulating BATF expression can enhance NK cell responses, potentially improving their ability to combat cancer and viral infections. By examining the effects of BATF on NK cell maturation and their immune responses, the research aims to identify new therapeutic strategies for enhancing anti-tumor and anti-viral immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers or viral infections that may benefit from enhanced NK cell activity.
Not a fit: Patients with conditions unrelated to NK cell function or those who do not have cancer or viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to fight cancers and viral infections.
How similar studies have performed: Previous research has shown promising results in enhancing NK cell function through various immunotherapeutic approaches, indicating potential success for this novel investigation.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kee, Barbara L. — University of Chicago
- Study coordinator: Kee, Barbara L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.